Latest On EyePoint Pharmaceuticals, Inc (EYPT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 14:28 EST | News | EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug Success | N/A |  |
| 2023-05-18 19:57 EST | News | Alimera jumps 48% on deal with EyePoint for eye disorder therapy Yutiq | N/A | |
| 2023-05-04 11:48 EST | News | EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-03 23:29 EST | News | EyePoint stock soars 20% after Q1 sees growth in Yutiq sales | N/A | |
| 2023-05-03 10:09 EST | News | EyePoint Pharmaceuticals GAAP EPS of -$0.56 beats by $0.13, revenue of $7.68M beats by $0.11M | N/A | |
About EyePoint Pharmaceuticals, Inc (EYPT):
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of read more...wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
General
- Name EyePoint Pharmaceuticals, Inc
- Symbol EYPT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:10
- Last Split Date2020-12-09
- Fiscal Year EndDecember
- IPO Date2005-01-27
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://eyepointpharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 3.93
- Price/Book (Most Recent Quarter) 16.32
- Enterprise Value Revenue 8.65
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.71
- Next Year EPS Estimate -$1.43
- Next Quarter EPS Estimate -$0.62
- Profit Margin -132%
- Operating Margin -107%
- Return on Assets -28%
- Return on Equity -338%
- Revenue 34.44 million
- Earnings Per Share -$0.72
- Revenue Per Share $2.68
- Gross Profit 11.19 million
- Quarterly Earnings Growth -17.4%
Highlights
- Market Capitalization 317.88 million
- EBITDA -56213000
- Analyst Target Price $19.25
- Book Value Per Share $1.02
Share Statistics
- Shares Outstanding 28.74 million
- Shares Float 19.88 million
- % Held by Insiders 73%
- % Held by Institutions 46.62%
- Shares Short 381742
- Shares Short Prior Month 350229
- Short Ratio 0.8
- Short % of Float 2%
- Short % of Shares Outstanding 1%
Technicals
- Beta 1.33
- 52 Week High $15.06
- 52 Week Low $3.51
- 50 Day Moving Average 12.02
- 200 Day Moving Average 7.3
Dividends
- Dividend Date 2020-12-09
- ExDividend Date N/A
- Dividend Yield 0%
EyePoint Pharmaceuticals, Inc (EYPT) Dividend Calendar:
EYPT's last dividend payment was made to shareholders on December 9, 2020.
EyePoint Pharmaceuticals, Inc (EYPT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
EyePoint Pharmaceuticals, Inc (EYPT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 5.21 million | N/A | N/A | 4.85 million | N/A |
| Income Before Tax | -15.47 million | N/A | N/A | -13.17 million | -10.41 million |
| Selling General Administrative | 11.59 million | N/A | N/A | 12.49 million | 11.55 million |
| Gross Profit | 4.67 million | N/A | N/A | 6.51 million | 3.18 million |
| Ebit | -13.03 million | N/A | N/A | -10.78 million | -8.99 million |
| Operating Income | -12.74 million | N/A | N/A | -11.44 million | -8.99 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 7.13 million | N/A | N/A | 7.49 million | 8.63 million |
| Cost of Revenue | 2.46 million | N/A | N/A | 980000 | 5.46 million |
| Total Other Income Expense Net | -905000 | N/A | N/A | N/A | -1.42 million |
| Net Income From Continuing Operations | -15.47 million | N/A | N/A | -13.17 million | -10.41 million |
| Net Income Applicable to Common Shares | N/A | -3.8 million | -12.95 million | -13.17 million | -10.41 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 2.93 million | -428000 | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -128000 | -26000 | N/A | N/A | N/A |
| Net Borrowings | N/A | 2.03 million | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | 4.9 million | N/A | N/A | N/A | N/A |
| Change to Operating Activities | N/A | -27000 | N/A | N/A | N/A |
| Change in Cash | 5.91 million | N/A | N/A | N/A | N/A |
| Total Cash from Operating Activities | 1.14 million | -5.12 million | N/A | N/A | N/A |
| Depreciation | 662000 | N/A | N/A | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | 132000 | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | 2.03 million | N/A | N/A | N/A | N/A |
| Change to Net Income | 2.72 million | 1.06 million | N/A | N/A | N/A |
| Capital Expenditures | 128000 | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 73.18 million | N/A | N/A | 63.82 million | 64.99 million |
| Total Stockholder Equity | 18.54 million | N/A | N/A | 16.47 million | 8.33 million |
| Other Current Liabilities | 687000 | 897000 | N/A | 551000 | 15000 |
| Total Assets | 91.72 million | N/A | N/A | 80.29 million | 73.32 million |
| Common Stock | N/A | 501.97 million | 125000 | 494.09 million | 472.78 million |
| Other Current Assets | N/A | N/A | N/A | N/A | 8.14 million |
| Retained Earnings | -510.68 million | -495.21 million | -491.41 million | -478.46 million | -465.29 million |
| Other Liabilities | N/A | 3.01 million | 3.03 million | 3.04 million | 3 million |
| Other Assets | N/A | 642000 | 150000 | 575000 | 507000 |
| Cash | 44.91 million | N/A | N/A | 26.3 million | 22.21 million |
| Total Current Liabilities | 14.89 million | 12.93 million | N/A | 10.3 million | 11.87 million |
| Other Stockholder Equity | N/A | 840000 | 840000 | 840000 | 840000 |
| Property, Plant & Equipment | N/A | 2.73 million | 3.26 million | 2.97 million | 3.08 million |
| Total Current Assets | 63.12 million | 47.59 million | N/A | 49.69 million | 42.07 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | N/A | -18.23 million | -22.25 million | -10.58 million | -19.34 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | 37.98 million | N/A | N/A | 47.72 million | 47.22 million |
| Inventory | 5.34 million | 3.64 million | N/A | 3.36 million | N/A |
| Accounts Payable | 4.81 million | 12.03 million | N/A | N/A | 11.38 million |
EyePoint Pharmaceuticals, Inc (EYPT) Chart:
EyePoint Pharmaceuticals, Inc (EYPT) News:
Below you will find a list of latest news for EyePoint Pharmaceuticals, Inc (EYPT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
EyePoint Pharmaceuticals, Inc (EYPT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest EYPT Trades:
EyePoint Pharmaceuticals, Inc (EYPT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-10-16 | DEF 14A (Other definitive proxy statements) | |
| 2020-10-16 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-10-16 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-10-08 | 8-K (Current report) | |
| 2020-10-07 | 8-K (Current report) | |
| 2020-10-06 | PRE 14A (Other preliminary proxy statements) | |
| 2020-09-15 | 8-K (Current report) | |
| 2020-09-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-26 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-20 | 8-K (Current report) | |
| 2020-08-12 | 8-K (Current report) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-05 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-07-13 | 8-K (Current report) | |
EyePoint Pharmaceuticals, Inc (EYPT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of EyePoint Pharmaceuticals, Inc (EYPT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 73%
Institutional Ownership: 4662%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-04 | George Elston | Chief Financial Officer | Buy | 10,000.00 | 0.48 | 4,800.00 | 40,000.00 | |
| 2020-08-24 | George Elston | Chief Financial Officer | Buy | 10,000.00 | 0.61 | 6,112.00 | 30,000.00 | |
| 2020-06-30 | Dario A. Paggiarino | Chief Medical Officer | Buy | 41,050.00 | 101,193.00 | | ||
| 2020-06-30 | David Scott Jones | SVP & Chief Commercial Officer | Buy | 41,050.00 | 41,050.00 | | ||
| 2020-06-30 | Nancy Lurker | President & CEO | Buy | 124,667.00 | 784,467.00 | | ||
| 2020-06-27 | Dario A. Paggiarino | Chief Medical Officer | Buy | 10,000.00 | 63,079.00 | | ||
| 2020-06-27 | Nancy Lurker | President & CEO | Buy | 40,000.00 | 659,800.00 | | ||
| 2020-06-14 | Dario A. Paggiarino | Chief Medical Officer | Buy | 14,200.00 | 57,247.00 | | ||
| 2020-06-14 | Nancy Lurker | President & CEO | Buy | 45,000.00 | 619,800.00 | | ||
| 2020-03-12 | George Elston | Chief Financial Officer | Buy | 10,000.00 | 0.96 | 9,600.00 | 20,000.00 | |
| 2020-03-10 | Nancy Lurker | President & CEO | Buy | 98,000.00 | 1.06 | 104,027.00 | 574,800.00 | |
| 2020-02-21 | Nancy Lurker | President & CEO | Buy | 137,174.00 | 476,800.00 | | ||
| 2019-11-15 | George Elston | Chief Financial Officer | Buy | 10,000.00 | 1.43 | 14,290.00 | 10,000.00 | |
| 2019-10-09 | David J Mazzo | Director | Buy | 33,333.00 | 1.95 | 64,999.35 | 200,083.00 | |
| 2019-09-06 | David J Mazzo | Director | Buy | 417.00 | 166,750.00 | | ||
| 2019-06-27 | Nancy Lurker | President & CEO | Buy | 40,000.00 | 325,200.00 | | ||
| 2019-06-27 | Dario A. Paggiarino | Chief Medical Officer | Buy | 10,000.00 | 48,437.00 | | ||
| 2019-06-27 | Leonard S Ross | Officer | Buy | 6,667.00 | 92,005.00 | | ||
| 2019-06-21 | MICHAEL W ROGERS | Director | Buy | 6,667.00 | 119,167.00 | | ||
| 2019-06-21 | David J Mazzo | Director | Buy | 8,333.00 | 166,333.00 | |